Flash Report 3 minutesRegister for Free AccessCVS Health (CVS) 4Q15 Results: Strong Growth Aided by Acquisitions Coresight Research February 10, 2016 Executive Summary CVS Health reported that 4Q15 net sales rose by 11.0% year over year, to $41.1 billion, slightly above the consensus estimate of $41.0 billion. Diluted non-GAAP EPS rose by 26.5% year over year, to $1.53, which was in line with the consensus estimate and within the guidance range of $1.51–$1.55. Pharmacy sales grew by 11.1%, to $26.5 billion, driven by growth in specialty drugs and the recent $10 billion acquisition of pharmaceutical distributor Omnicare. The company reaffirmed its FY16 forecast of non-GAAP EPS of $5.73–$5.88, in line with consensus of $5.82. For 1Q, CVS expects non-GAAP EPS of $1.14–$1.17, slightly below the consensus estimate of $1.18. Please Login to read the full report. Not a member? Register for a free user account. This document was generated for Other research you may be interested in: Retail Shrink and ORC: Theft and Fraud Remain Top Challenges for Food RetailersWho Shops Where? 2023 Shopper Demographics: US Consumer Tracker Extra, August 2023Earnings Insights 4Q23, Week 5: Bath & Body Works, TJX Companies and Urban Outfitters See Sales Growth; Best Buy, Lowe’s and Others See Sales DeclineWeekly US and UK Store Openings and Closures Tracker 2024, Week 40: UK Store Closures Surpass 1,000